SB 825 - This act requires a pharmacist, pharmacist technician, or pharmacy intern to provide notification to the patient, a family member, other relative, or any other person identified by the patient before interchanging one manufacturer of an anti-epileptic drug for another manufacturer of an anti-epileptic drug in instances where the patient's epilepsy or seizures is currently being controlled on a specific drug, strength, dosage form, and dosing regimen from a specific manufacturer. The prescriber of the medication must also be notified prior to the interchange. This requirement shall not apply to prescriptions dispensed for inpatients of a hospital, a long-term care facility or inpatients of a mental health or residential facility. This act is similar to SB 1094 (2008). ADRIANE CROUSE